Partner with Jiksak: Series C Funding to Scale Next-Gen Neuron Selective Drug Delivery & Discovery

Jiksak Neuron Drug Delivery System (NDDS): Transforming CNS Therapeutics

Breakthrough Innovation

Jiksak’s NDDS is a first-in-class platform that bypasses the Blood-Brain Barrier (BBB) and Blood-Spinal Cord Barrier (BSCB) by utilizing motor neuron axons as a natural delivery route. This innovation enables precise, neuron-selective drug delivery directly into the central nervous system (CNS) via intravenous injection — eliminating the need for invasive intrathecal administration. The result is higher drug concentration inside neurons, fewer off-target effects, and improved patient experience.

Therapeutic Pipeline & Clinical Path

Jiksak currently has two therapeutic pipelines in development, targeting high-value indications in neurodegenerative disease and neuropathic conditions. With preclinical progress advancing on schedule, Jiksak aims to initiate first-in-human clinical trials by 2028, marking a major milestone toward commercialization.

Competitive Advantage

• Neuron-Specific Targeting – Dramatically reduces systemic exposure and off-target effects.

• Intravenous Delivery – More patient-friendly than intrathecal injection, enabling easier adoption.

• Platform Scalability – Suitable for oligonucleotides, biologics, and small molecules across multiple indications.

• Faster Development Timelines – Potential to rescue shelved CNS assets that failed due to BBB penetration issues.

• Partnership & Licensing Ready – Open for strategic collaborations with pharma/biotech.

Market Opportunity & Growth

The global neurotherapeutics market is expected to surpass $150B by 2030. NDDS positions Jiksak to capture significant market share as a platform technology that can be licensed, co-developed, and scaled across a broad range of CNS indications — creating multiple revenue streams and pipeline-in-a-product potential.

Investment Thesis

Series C funding will accelerate preclinical development, scale manufacturing, and establish partnerships leading into clinical trials. Investors have the opportunity to support a transformational drug delivery platform with a clear regulatory path, near-term clinical milestones, and strong growth potential in a multi-billion-dollar market.